We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 151.18 | 237 | 09:32:42 |
From May 2019 to May 2024
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said it received Health Canada approval of the cancer drug Imbruvica in combination with obinutuzumab for treatment-naive patients with active chronic lymphocytic leukemia, or CLL.
Janssen said the indication marks the first approval for a non-chemotherapy combination regimen for treatment-naive patients with CLL, one of the most common types of leukemia in adults.
It also marks the ninth indication for Imbruvica in Canada since its first approval in November 2014, Janssen said.
Imbruvica is commercialized in Canada by Janssen, which jointly develops the drug with AbbVie Inc.'s (ABBV) Pharmacyclics LLC.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 08, 2019 09:02 ET (14:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
